Patient investors who buy into innovative companies with clear-cut competitive advantages have a real chance to see their initial investment compound many times over. There's no sugarcoating it: telehealth giant Teladoc Health (NYSE: TDOC) was one of 2021's biggest disappointments. After skyrocketing during the initial stages of the coronavirus pandemic, concerns about larger-than-expected losses tied to its Livongo Health acquisition, as well as worries about slowing growth in an eventual post-pandemic world, pushed shares more than 70% below their all-time high.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting